Saturday 17 October 2026
Export NEXI’s income statement to Excel — free account
NexImmune, Inc.
NEXI Healthcare Biotechnology
Operating cash flow growth for three consecutive years.
0.00
0.00
NaN
Follow NEXI
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
1.06 | 3.62 | 11.96 | 0.31 | 3.65 | 4.11 | — |
Net Debt/EBITDA |
0.10 | 0.56 | 1.56 | (0.51) | 0.50 | (1.76) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 169.17% | 0.00% | 247.82% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.28) | 0.00 | (1.45) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.97 | 0.82 | 0.89 | 0.80 | 0.84 | 0.75 | — |
Capex/Depreciation |
(0.04) | (1.18) | (2.70) | (1.40) | (2.85) | 0.00 | — |
Interest Coverage |
— | (94.95) | (58.83) | (16.55) | (2,861.07) | (97.23) | — |
| (180.64%) | (107.71%) | (712.92%) | 58.99% | 69.02% | 44.33% | — | |
| (125.24%) | (93.23%) | (100.22%) | (264.97%) | (166.59%) | (210.81%) | — | |
ROIC |
(7,175.66%) | 0.00% | (1,775.29%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(1,937.14%) | (198.47%) | (61.42%) | 210.47% | (219.15%) | (135.19%) | — |
Average Days of Receivables |
— | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(29.99) | (54.41) | (59.62) | (543.22) | (416.56) | (12.34) | — |
Cash per Share |
3.07 | 36.05 | 101.42 | 101.57 | 205.71 | 13.39 | — |
Shareholders Equity per Share |
3.34 | 33.56 | 103.74 | (1,381.97) | (867.13) | (26.90) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
3.34 | 33.56 | 103.74 | (1,381.97) | (867.13) | (26.90) | — |
Free Cash Flow |
(31.47) | (52.37) | (48.14) | (27.27) | (20.66) | (11.12) | — |
Working Capital |
0.32 | 27.04 | 79.06 | (18.63) | 8.01 | 9.33 | — |
Capital Expenditures |
(0.04) | (1.17) | (2.35) | (0.86) | (1.25) | (0.94) | — |
Net Current Asset Value |
0.32 | 26.61 | 79.01 | (72.28) | (45.69) | (26.05) | — |
| Other line items | |||||||
Quick Ratio |
0.63 | 3.36 | 11.35 | 0.19 | 3.37 | 4.02 | — |
Depreciation/Fixed assets |
0.76 | 0.22 | 0.20 | 0.21 | 0.17 | 0.12 | — |
Cash ROIC |
(467.53%) | (78.16%) | (29.06%) | 60.39% | 62.98% | (48.62%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | — |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,535.46 | — |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(29.95) | (53.19) | (56.71) | (525.99) | (391.44) | (12.34) | — |
Capex per Share |
(0.04) | (1.22) | (2.91) | (17.23) | (25.12) | 0.00 | — |
Average Payables |
1.86 | 1.71 | 1.90 | 1.97 | 1.02 | 1.02 | — |
Average Assets |
25.83 | 67.05 | 51.17 | 12.51 | 13.93 | 7.07 | — |
Average Common Equity |
17.91 | 58.03 | 7.19 | (56.19) | (33.62) | (33.62) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates